可溶性CD30升高与肺移植后闭塞性细支气管炎综合征的发生相关。
Elevated soluble CD30 correlates with development of bronchiolitis obliterans syndrome following lung transplantation.
作者信息
Fields Ryan C, Bharat Ankit, Steward Nancy, Aloush Aviva, Meyers Brian F, Trulock Elbert P, Chapman William C, Patterson G Alexander, Mohanakumar Thalachallour
机构信息
Department of Surgery, Washington University School of Medicine, St. Louis, MO, USA.
出版信息
Transplantation. 2006 Dec 27;82(12):1596-601. doi: 10.1097/01.tp.0000241076.46033.4c.
BACKGROUND
The long-term function of lung transplants is limited by chronic rejection (bronchiolitis obliterans syndrome, BOS). Due to lack of specific markers, BOS is diagnosed clinically. Because there is strong evidence that alloimmunity plays a significant role in the pathogenesis of BOS, we investigated whether soluble CD30 (sCD30), a T-cell activation marker, would correlate with BOS.
METHODS
Sera collected serially from BOS+ (n = 20) and matched BOS- (n = 20) lung transplant (LT) patients were analyzed for sCD30 by enzyme-linked immunosorbent assay. Pretransplant sera and sera from normal donors were also analyzed.
RESULTS
PreLT levels were comparable to normal subjects. However, posttransplant there was a significant elevation in sCD30 levels during BOS development in all BOS+ patients, compared to BOS- (mean 139.8+/-10.7 vs. 14.8+/-2.7 U/ml, P < 0.001). sCD30 levels declined in the BOS+ patients but were still elevated compared to BOS- (48.52+/-5.04 vs. 7.19+/-2.9, P < 0.0001).
CONCLUSIONS
We conclude that sCD30 may represent a novel marker to monitor the development of BOS.
背景
肺移植的长期功能受到慢性排斥反应（闭塞性细支气管炎综合征，BOS）的限制。由于缺乏特异性标志物，BOS通过临床诊断。因为有强有力的证据表明同种免疫在BOS的发病机制中起重要作用，我们研究了T细胞活化标志物可溶性CD30（sCD30）是否与BOS相关。
方法
通过酶联免疫吸附测定法分析从BOS阳性（n = 20）和匹配的BOS阴性（n = 20）肺移植（LT）患者中连续收集的血清中的sCD30。还分析了移植前血清和正常供体的血清。
结果
移植前水平与正常受试者相当。然而，与BOS阴性患者相比，所有BOS阳性患者在BOS发展过程中移植后sCD30水平显著升高（平均139.8±10.7对14.8±2.7 U/ml，P <0.001）。BOS阳性患者的sCD30水平下降，但与BOS阴性患者相比仍升高（48.52±5.04对7.19±2.9，P <0.0001）。
结论
我们得出结论，sCD30可能代表一种监测BOS发展的新型标志物。
Zotero 插件